Carisma Therapeutics

Developer of chimeric antigen receptor macrophages for the treatment of cancer

placePhiladelphia, Pennsylvania, United States calendar_todayFounded 2016 groups34 employees language carismatx.com

Registered entities

Innovation

13 patent families (1 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace accelerating. Cited 306 times.

YearFilings
20212
20223
20235
202411
20259
20261

Investor mix

18 investors on record; lead investors include AbbVie, Symbiosis, Livzon Pharmaceutical, Solasta Ventures.

Investor typeCountShare
Venture capital1056%
Private equity16%
Bank & private debt16%
Other / undisclosed633%
Coming soon